These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 7828354

  • 1. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
    Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Pumar A, Villamil F, Astorga R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [Abstract] [Full Text] [Related]

  • 3. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 4. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F, Peñalva A, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [Abstract] [Full Text] [Related]

  • 5. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M, Barreiro J, Peñalva A, Peino R, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome.
    Micić D, Kendereski A, Popović V, Sumarac M, Zorić S, Macut D, Dieguez C, Casanueva F.
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):385-90. PubMed ID: 8959075
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
    Micic D, Popovic V, Kendereski A, Macut D, Casanueva FF, Dieguez C.
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):191-4. PubMed ID: 7734029
    [Abstract] [Full Text] [Related]

  • 8. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.
    Borges MH, DiNinno FB, Lengyel AM.
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):713-8. PubMed ID: 9274702
    [Abstract] [Full Text] [Related]

  • 9. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
    [Abstract] [Full Text] [Related]

  • 10. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D, Popovic V, Kendereski A, Peino R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [Abstract] [Full Text] [Related]

  • 11. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
    Leal-Cerro A, Venegas E, Garcia-Pesquera F, Jimenez LM, Astorga R, Casanueva FF, Dieguez C.
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
    [Abstract] [Full Text] [Related]

  • 12. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R.
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [Abstract] [Full Text] [Related]

  • 13. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A, Bossoni S, Bodini C, Ferrari C, Pizzocolo G, Scalvini T, Schettino M, Wehrenberg WB.
    Horm Res; 1991 Sep; 35(3-4):99-103. PubMed ID: 1806475
    [Abstract] [Full Text] [Related]

  • 14. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [Abstract] [Full Text] [Related]

  • 15. Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
    Correa-Silva SR, Nascif SO, Lengyel AM.
    Pituitary; 2006 Mar; 9(2):101-7. PubMed ID: 16832586
    [Abstract] [Full Text] [Related]

  • 16. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 17. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 18. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
    Pinto AC, Finamor FE, Lengyel AM.
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.
    Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1994 Aug; 79(2):456-60. PubMed ID: 8045963
    [Abstract] [Full Text] [Related]

  • 20. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.